Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease systemic scleroderma
Comorbidity C0024115|lung disease
Sentences 37
PubMedID- 23588945 Can serum surfactant protein d or cc-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis.
PubMedID- 25709096 Where are we going in the management of interstitial lung disease in patients with systemic sclerosis.
PubMedID- 21538327 systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
PubMedID- 24838199 Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct.
PubMedID- 23401350 Does c-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis.
PubMedID- 26392856 We discuss a case that demonstrates the difficulties in making a confident diagnosis of interstitial lung disease (ild) associated with systemic sclerosis (ssc).
PubMedID- 22015621 Intravenous cyclophosphamide pulse therapy (ivcy) exerts its efficacy against interstitial lung disease (ild) associated with systemic sclerosis (ssc) by restoring vascular injuries as well as aberrant immune activation.
PubMedID- 23697634 Background: to determine the usefulness of ca 15.3 as a candidate biomarker in systemic sclerosis (ssc) patients with interstitial lung disease (ild).
PubMedID- 23925736 Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.
PubMedID- 23940607 The muc5b variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the european caucasian population.
PubMedID- 25282395 Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (ssc-ild): efficacy of maintenance immunosuppression in responders and non-responders.
PubMedID- 26079155 Exhaled nitric oxide (no) is increased as a result of lung inflammation, which in turn causes subsequent interstitial lung disease in patients with systemic sclerosis (ssc).
PubMedID- 25650330 Introduction: interstitial lung disease occurs frequently in patients with systemic sclerosis (ssc).
PubMedID- 22075605 We aimed to investigate the clinical significance of serum levels of secretory leukocyte protease inhibitor (slpi), which is widely expressed in lung tissues and serves as a useful marker reflecting the activity of various lung diseases, in patients with systemic sclerosis (ssc).
PubMedID- 25356253 Twenty systemic sclerosis patients with associated interstitial lung disease were treated with imatinib (up to 600 mg/day).
PubMedID- 25665185 Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus.
PubMedID- 26315813 Objectives: to evaluate a new ultrasound sign, pleural irregularity (pi), for the study of interstitial lung disease (ild) in patients with systemic sclerosis (ssc) and antisynthetase syndrome (ass).
PubMedID- 21458128 Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.
PubMedID- 22610787 Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis.
PubMedID- 23764864 Predictors of exercise-induced oxygen desaturation in systemic sclerosis patients with interstitial lung disease.
PubMedID- 22540429 Serum levels of adam12-s: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis.
PubMedID- 25300701 Objectives: to assess the long-term efficacy and safety of single and multiple courses of rituximab therapy in systemic sclerosis (ssc) patients with and without lung disease.
PubMedID- 25629053 To evaluate the performance of a computerized-aided method (cam) for quantification of interstitial lung disease (ild) in patients with systemic sclerosis and to determine its correlation with the conventional visual reader-based score (covr) and the pulmonary function tests (pfts).
PubMedID- 21978705 systemic sclerosis (ssc) is associated with interstitial lung diseases.
PubMedID- 25624597 Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis.
PubMedID- 20404807 Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.
PubMedID- 24814462 Successful use of intravenous cyclophosphamide pulse therapy for interstitial lung disease in a patient with systemic sclerosis on hemodialysis.
PubMedID- 21474572 Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
PubMedID- 23660398 Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis.
PubMedID- 21996293 Increased frequency of circulating th22 in addition to th17 and th2 lymphocytes in systemic sclerosis: association with interstitial lung disease.
PubMedID- 21618205 Objective: patients with systemic sclerosis-associated interstitial lung disease (ssc-ild) are thought to have the greatest decline in lung function (forced vital capacity [fvc]% predicted) in the early years after disease onset.
PubMedID- 22084615 Reduced hypoxia risk in a systemic sclerosis patient with interstitial lung disease after long-term pulmonary rehabilitation.
PubMedID- 20425529 Although there are likely commonalities in the pathophysiologic mechanisms and clinical progression among all fibrosing lung diseases, a better understanding of features unique to systemic sclerosis-associated interstitial lung disease is essential to the development of more effective monitoring and treatment strategies.
PubMedID- 24801572 The aim of this study was to evaluate efficacy of azathioprine (aza) and cyclophosphamide (cyc) as a therapeutic regimen for interstitial lung disease associated with systemic sclerosis (ssc).
PubMedID- 23378460 Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
PubMedID- PMC3329084 These findings suggest that the development of pulmonary arterial hypertension is probably independent of the existence of interstitial lung disease in patients with systemic sclerosis.
PubMedID- 22972016 Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis.

Page: 1